Pharma RSS Digest - 2026-05-08

Overview

Tuesday's session was dominated by a major bolt-on acquisition in ophthalmology and a serious medical device recall. Bayer moved to acquire Perfuse Therapeutics for up to $2.45 billion, aiming to shore up its flagship Eylea franchise ahead of patent expiration in mid-2027. Meanwhile, the FDA escalated a syringe-related recall to its most serious classification, citing risks of biohazard exposure and other life-threatening complications. The data slate was otherwise light, leaving these two developments to shape sentiment across pharma and device subsectors.

Key Developments

Bayer bets on ophthalmology pipeline with Perfuse acquisition. Bayer announced an agreement to acquire Perfuse Therapeutics for up to $2.45 billion—$300 million in cash upfront and up to $2.15 billion tied to future milestones. Perfuse's lead candidate PER-001 is an intravitreal endothelin receptor antagonist that delivered meaningful efficacy signals in two Phase IIa studies: responder rates of 22-38% in open-angle glaucoma versus 0% for controls, and contrast-sensitivity gains in diabetic retinopathy that far outpaced a worsening control arm. The deal gives Bayer a pipeline-in-a-product asset as its $8 billion-plus Eylea franchise faces increasing pressure from generic competition starting in 2027. Bayer's Q1 2026 Eylea U.S. sales already declined 10% year-over-year. The transaction requires Perfuse shareholder approval and antitrust clearance, and PER-001 still needs Phase III trials and regulatory sign-off before commercialization.

Regulatory / Approval

FDA escalates convenience kit recall to Class I following injury reports. The agency upgraded a recall of Medical Action Industries convenience kits containing Namic RA syringes to Class I—the most serious classification—on May 7, 2026. The rotating adaptors in these syringes can unwind during use, creating loose connections that may lead to biohazard exposure, blood loss, infection, air embolism, serious injury, or death. Four serious injuries had been reported as of mid-March, with zero deaths. The recall affects multiple lots, and the FDA noted that all distributed units carry potential for failure, suggesting a systemic design or manufacturing issue rather than a lot-specific defect. Healthcare facilities must identify, label, and destroy affected syringes. The root cause remains undisclosed, and whether other Medline syringe models are affected is unconfirmed.

Safety / Pharmacovigilance

Watchlist

• Regulatory review timeline for the Bayer-Perfuse deal as antitrust scrutiny of pharma acquisitions intensifies. [link]
• Phase III design and endpoints for PER-001, which will determine how quickly the asset could reach filing. [link]
• Broader Medline syringe portfolio exposure to determine if the unwinding failure mode extends beyond the Namic RA line.
• Device supply chain impact on healthcare facilities that rely on affected convenience kits for surgical procedures.